ARVO 2021: Brolucizumab Non-Inferior to Aflibercept for Diabetic Macular Edema Despite Longer Dosing Intervals
Brolucizumab may have a superior impact on central subfield thickness and fluid resolution
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.